[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100553987":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":81,"collaborators":25,"id":84,"slug":85,"hasResults":86,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":86,"sex":92,"minAge":93,"maxAge":25,"enrollmentInfo":94,"targetDuration":25,"studyType":97,"phases":98,"briefSummary":100,"conditions":101,"keywords":25,"overallStatus":39,"whyStopped":25,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":114},{"fullName":5,"class":6},"Saint Petersburg State University, Russia","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intraoperative strategy","ACTIVE_COMPARATOR","Policy of no routine use of fibrinolysis inhibitors after surgery. Patients in this group will receive the center's routine prophylactic dose of fibrinolysis inhibitor, which is 100%, during surgery.",[13],"Other: No routine fibrinolysis inhibitors after surgery",{"label":15,"type":16,"description":17,"interventionNames":18},"Intraoperative and postoperative strategy","EXPERIMENTAL","Policy of routine use of fibrinolysis inhibitors 4 hours after surgery. Patients in this group will receive 70% of the routine prophylactic dose of fibrinolysis inhibitor administered by the center during surgery. Additionally, they will receive 30% of the dose as an IV infusion within 4 hours after the surgery.",[19],"Other: Routine fibrinolysis inhibitors after surgery",[21,26],{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"No routine fibrinolysis inhibitors after surgery","Tranexamic acid or epsilon-aminocaproic acid should be administered intravenously during surgery. The dosage and method of administration should be followed according to the routine practice of the participating site.",[9],null,{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Routine fibrinolysis inhibitors after surgery","During surgery, it is recommended to administer 70% of the routine dose of Tranexamic acid or epsilon-aminocaproic acid intravenously. Following the surgery, the remaining 30% of this dose should be administered as a continuous intravenous infusion over the course of the first 4 hours.",[15],[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Sergey Efremov, PhD","CONTACT","+79137946090","efremovsergm@gmail.com",[37,70],{"facility":38,"status":39,"city":40,"state":25,"zip":25,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Cardiac surgery department, Saint-Petersburg state university hospital","RECRUITING","Saint Petersburg","Russia","RU",{"type":44,"coordinates":45},"Point",[46,47],30.31413,59.93863,{"lat":47,"lon":46},[50,53,55,58,60,62,64,66,68],{"name":51,"role":33,"phone":52,"phoneExt":25,"email":35},"Sergey Efremov, MD, PhD","79137946090",{"name":51,"role":54,"phone":25,"phoneExt":25,"email":25},"PRINCIPAL_INVESTIGATOR",{"name":56,"role":57,"phone":25,"phoneExt":25,"email":25},"Arina Malarenko, MD","SUB_INVESTIGATOR",{"name":59,"role":57,"phone":25,"phoneExt":25,"email":25},"Polina Turina, MD",{"name":61,"role":57,"phone":25,"phoneExt":25,"email":25},"Andrey Maslov, MD",{"name":63,"role":57,"phone":25,"phoneExt":25,"email":25},"Anna Solovieva",{"name":65,"role":57,"phone":25,"phoneExt":25,"email":25},"Tatiana Ionova, MD, PhD",{"name":67,"role":57,"phone":25,"phoneExt":25,"email":25},"Tatiana Nikitina, PhD",{"name":69,"role":57,"phone":25,"phoneExt":25,"email":25},"Ivan Labetov, MD",{"facility":71,"status":72,"city":40,"state":25,"zip":25,"country":41,"countryCode":42,"cosmosGeoPoint":73,"geoPoint":75,"contacts":76},"St. Petersburg State University Hospital","NOT_YET_RECRUITING",{"type":44,"coordinates":74},[46,47],{"lat":47,"lon":46},[77,79,80],{"name":78,"role":33,"phone":25,"phoneExt":25,"email":25},"Efremov Sergey, MD, PhD",{"name":56,"role":57,"phone":25,"phoneExt":25,"email":25},{"name":51,"role":54,"phone":25,"phoneExt":25,"email":25},{"type":54,"investigatorFullName":82,"investigatorTitle":83,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Efremov Sergey","Deputy Director for Science","100553987","extended-perioperative-administration-of-fibrinolysis-inhibitors-after-cardiac-surgery-100553987",false,"NCT06493227","Extended Perioperative Administration of Fibrinolysis Inhibitors After Cardiac Surgery","The Practice of Routine Extended Perioperative Administration of Fibrinolysis Inhibitors to Reduce the Risk of Bleeding in Cardiac Surgery. Multicenter Prospective Randomized Cluster Crossover Study","PRIORITY","Inclusion Criteria:\n\n1. A hospital that performs a minimum of 250 open heart interventions per year.\n2. Consent from hospital physicians regarding the prophylactic use of fibrinolysis inhibitors (more than 95% of physicians involved in the treatment of adult patients (\\>18 years) agree to adhere to the strategy of using fibrinolysis inhibitors as prescribed by the study protocol).\n\nExclusion Criteria:\n\n* Hospital does not meet inclusion criteria","ALL","18 Years",{"count":95,"type":96},1373,"ESTIMATED","INTERVENTIONAL",[99],"NA","PRIORITY is a pragmatic, multi-center, cluster crossover trial that aims to evaluate whether implementing a policy of routine extended (intraoperative and 4 hour after transfer to ICU) use of fibrinolysis inhibitors leads to a decrease in post-operative blood transfusion compared to a policy that only involves intraoperative use.",[102,103,104],"Thoracic Surgery","Heart Diseases","Fibrinolysis Shutdown","2025-01-22",{"date":107,"type":108},"2025-01-27","ACTUAL",{"date":110,"type":108},"2024-08-01",{"date":112,"type":96},"2026-06-01",{"name":5,"class":6},2]